

Tu

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

AMENDMENT TRANSMITTAL		Docket Number: 1662/60707		
Application Number 10/621,623	Filing Date July 16, 2003	Examiner Laura Stockton	Art Unit 1626	
Invention Title Novel Synthesis of Irbesartan		Inventor(s) Dolitzky, et al.		

Address to:
Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: Non-Fee Amendment
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: 10(25105
Signature: Agrees Xu

Sir:

Transmitted herewith for filing is a response to the Restriction Requirement mailed September 29, 2005 for the above-identified application.

No additional fees are believed due. However, if any fees are due the Commissioner is authorized to charge deposit account No. 11-0600 for such fees. A copy of this letter is enclosed for that purpose.

Dated: October 25, 2005

John B. Starr, Jr. (Reg. No. 44,474)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646

PATENT Ser. No. 10/621,623 Atty. Docket No. 1662/60707

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dolitzky, et a

Serial No.:

10/621,623

Filed:

July 16, 2003

For:

Novel Synthesis of Irbesartan

Docket No.:

1662/60707

Address to: Non-Fee Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with sufficient postage with the United States Postal Service as first class mail in an envelope addressed to:

1626

Laura Stockton

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

22313-1430 on

Date: 10125105

Art Unit:

xaminer:

Signature:

AMRS Xu

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the communication from the Office mailed September 29, 2005, applicants hereby elect, without traverse, the claims of Group II (ie. claims 11-18) for examination in the present application. Applicants expressly reserve the right to prosecute the subject matter of the non-elected claims in one or more continuation or divisional applications.

If, in the opinion of the Examiner, a telephone conference would advance the prosecution of the Application, the Examiner is invited to telephone the undersigned attorney.

Dated: October 25, 2005

By:

John B. Starr, Jr.

(Reg. No. 44,474)

KENYON & KENYON

One Broadway

New York, New York 10004

(212) 908-6257 (Telephone-direct)

(212) 425-5288 (Fax)

CUSTOMER NUMBER 26646